Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853242 · ClinicalTrials.gov registry record · Phase 2
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 349
- Enrollment target
NCT00853242: Completed Phase 2 study, sponsored by Genzyme, a Sanofi Company.
NCT00853242 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 349 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00853242, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 349 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.
Interventions
- DRUG Placebo
- DRUG Sevelamer carbonate
- DRUG Genz-644470
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00853242 record still lists
NCT00853242 is an interventional study that assigns participants to a tested intervention. The registered 349 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00853242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00853242 about?
NCT00853242 is a clinical study titled "Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis". The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.
What is the current status of trial NCT00853242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 349 participants. The study started on 2009-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00853242?
The interventions under investigation include: Placebo (DRUG), Sevelamer carbonate (DRUG), Genz-644470 (DRUG).
Who is sponsoring clinical trial NCT00853242?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00853242's enrollment target sits among peer trials
349 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia